The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Full approval will depend on verification of clinical benefit in a confirmatory trial
Subscribe To Our Newsletter & Stay Updated
